公开(公告)号：WO02085384A3

公开(公告)日：2003-08-21

申请号：PCT/CA0200546

申请日：2002-04-23

Applicant: NUCRYST PHARM CORP ,  BURRELL ROBERT EDWARD ,  YIN HUA QING ,  NAYLOR ANTONY GEORGE ,  MOXHAM PETER HOWARD ,  CHOLOWSKI WALTER CARLTON THEOD ,  BOWLBY LEONARD SALVIN ,  FIELD DAVID JAMES

Inventor： BURRELL ROBERT EDWARD ,  YIN HUA QING ,  NAYLOR ANTONY GEORGE ,  MOXHAM PETER HOWARD ,  CHOLOWSKI WALTER CARLTON THEOD ,  BOWLBY LEONARD SALVIN ,  FIELD DAVID JAMES

IPC: A61K9/02 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08 ,  A61K9/10 ,  A61K9/107 ,  A61K9/12 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/51 ,  A61K9/68 ,  A61K9/70 ,  A61K33/24 ,  A61K33/38 ,  A61K33/40 ,  A61K47/34 ,  A61K47/38 ,  A61L15/44 ,  A61L15/46 ,  A61L17/14 ,  A61L27/30 ,  A61L29/10 ,  A61L31/08 ,  A61P1/00 ,  A61P1/02 ,  A61P9/00 ,  A61P11/00 ,  A61P11/02 ,  A61P11/04 ,  A61P13/00 ,  A61P13/08 ,  A61P15/00 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P17/08 ,  A61P17/10 ,  A61P19/00 ,  A61P19/02 ,  A61P27/16 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/10 ,  A61P35/00 ,  A61P43/00 ,  A61L27/54 ,  A61F13/00 ,  A61L31/16 ,  B22F9/02

CPC classification number: A61K9/0024 ,  A01N59/16 ,  A61K9/0019 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/14 ,  A61K9/7007 ,  A61K33/24 ,  A61K33/38 ,  A61K33/40 ,  A61K47/34 ,  A61K47/38 ,  A61L15/46 ,  A61L17/145 ,  A61L27/30 ,  A61L29/10 ,  A61L31/082 ,  A61L2300/102 ,  A61L2300/104 ,  A61L2300/404 ,  A61L2300/452 ,  A61L2300/606 ,  A61L2300/624 ,  A61L2300/63 ,  Y10S424/15 ,  Y10S514/825 ,  Y10S514/826 ,  Y10S514/829 ,  Y10S514/83 ,  Y10S514/849 ,  Y10S514/851 ,  Y10S514/853 ,  Y10S514/861 ,  Y10S514/862 ,  Y10S514/864 ,  Y10S514/865 ,  Y10S514/88 ,  Y10S514/881 ,  Y10S514/882 ,  Y10S514/886 ,  Y10S514/887 ,  Y10S514/90 ,  Y10S514/901 ,  Y10S514/902 ,  Y10S514/912 ,  Y10S514/914 ,  Y10S514/925 ,  Y10S514/931 ,  Y10S514/932 ,  Y10S514/933 ,  Y10S514/934 ,  Y10S514/944 ,  Y10S514/951 ,  Y10S514/953 ,  Y10S514/954 ,  Y10S514/956 ,  Y10S514/958 ,  Y10S514/964 ,  Y10S514/965 ,  Y10S514/966 ,  Y10S514/967 ,  Y10S514/968 ,  Y10S514/969 ,  Y10T428/31855 ,  A61K2300/00 ,  A01N25/04 ,  A01N25/10 ,  A01N25/12

Abstract: The invention provides methods and kits to form water swellable gel coatings, preferably lubricious coatings, on substrates, and coated substrates thus formed. The coatings contain one or more antimicrobial metals formed with atomic disorder, together with one or more antimicrobial metals formed with atomic disorder such that the coatings provide an antimicrobial and anti-inflammatory effect when wet. The invention also provides a method to produce metal powders by sputtering a coating onto a moving surface, and then scraping the coating with one or more scrapers to produce the metal powder. The method is particularly useful for producing large amounts of nanocrystalline antimicrobial metal powders formed with atomic disorder, useful in the water swellable gel coatings on this invention.

Abstract translation: 本发明提供了在基底上形成水可溶胀凝胶涂层，优选润滑涂层的方法和试剂盒，以及如此形成的涂覆的基底。 涂层含有一种或多种由原子紊乱形成的抗微生物金属，以及一种或多种由原子紊乱形成的抗微生物金属，使得涂层在湿润时提供抗微生物和抗炎作用。 本发明还提供了通过将涂层溅射到移动表面上然后用一个或多个刮刀刮擦涂层以产生金属粉末来生产金属粉末的方法。 该方法特别适用于生产大量由原子紊乱形成的纳米晶体抗微生物金属粉末，可用于本发明的水溶胀性凝胶涂层。

公开(公告)号：WO0209729A3

公开(公告)日：2002-12-12

申请号：PCT/CA0101078

申请日：2001-07-27

Applicant: NUCRYST PHARM CORP ,  BURRELL ROBERT EDWARD ,  WRIGHT JOHN BARRYMORE ,  LAM KAN

Inventor： BURRELL ROBERT EDWARD ,  WRIGHT JOHN BARRYMORE ,  LAM KAN

IPC: A61K9/06 ,  A61K8/19 ,  A61K9/08 ,  A61K9/70 ,  A61K33/24 ,  A61K33/38 ,  A61K47/32 ,  A61K47/38 ,  A61P17/06 ,  A61P17/12 ,  A61Q17/00 ,  A61Q19/00

CPC classification number: A61Q17/005 ,  A61K8/19 ,  A61K9/0014 ,  A61K9/7023 ,  A61K33/38 ,  A61K47/32 ,  A61K47/38 ,  A61K2800/413 ,  A61Q19/00 ,  B82Y5/00 ,  Y10S514/86 ,  Y10S514/861 ,  Y10S514/863 ,  Y10S514/864 ,  Y10S514/886 ,  Y10S514/887 ,  Y10S514/944 ,  Y10S514/951 ,  Y10S514/963

Abstract: The invention relates to the use of one or more noble metals selected from silver, gold, platinum, and palladium but most preferably silver, in a nanocrystalline form, for the treatment of a hyperproliferative skin disorder or disease such as psoriasis. Among the noble metals, silver is preferred for such treatment. The nanocrystalline noble metal of choice may be used in the form of a nanocrystalline coating of one or more noble metals, a nanocrystalline powder of one or more noble metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more noble metals.

Abstract translation: 本发明涉及一种或多种选自银，金，铂和钯，但最优选银为纳米晶体形式的贵金属用于治疗过度增殖性皮肤病症或疾病如牛皮癣的用途。 在贵金属中，银用于这种处理是优选的。 所选择的纳米晶体贵金属可以以一种或多种贵金属的纳米晶涂层，一种或多种贵金属的纳米晶体粉末或含有来自纳米晶体粉末的溶解物质的溶液或一种或多种贵族 金属。

公开(公告)号：WO02085386A2

公开(公告)日：2002-10-31

申请号：PCT/CA0200548

申请日：2002-04-23

Applicant: NUCRYST PHARM CORP ,  BURRELL ROBERT EDWARD ,  WRIGHT JOHN BARRYMORE ,  LAM KAN

Inventor： BURRELL ROBERT EDWARD ,  WRIGHT JOHN BARRYMORE ,  LAM KAN

IPC: A61K9/02 ,  A61K9/00 ,  A61K9/06 ,  A61K9/08 ,  A61K9/10 ,  A61K9/107 ,  A61K9/12 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/51 ,  A61K9/68 ,  A61K9/70 ,  A61K33/24 ,  A61K33/38 ,  A61K33/40 ,  A61K47/34 ,  A61K47/38 ,  A61L15/44 ,  A61L15/46 ,  A61L17/14 ,  A61L27/30 ,  A61L29/10 ,  A61L31/08 ,  A61P1/00 ,  A61P1/02 ,  A61P9/00 ,  A61P11/00 ,  A61P11/02 ,  A61P11/04 ,  A61P13/00 ,  A61P13/08 ,  A61P15/00 ,  A61P17/00 ,  A61P17/02 ,  A61P17/04 ,  A61P17/06 ,  A61P17/08 ,  A61P17/10 ,  A61P19/00 ,  A61P19/02 ,  A61P27/16 ,  A61P29/00 ,  A61P31/00 ,  A61P31/04 ,  A61P31/10 ,  A61P35/00 ,  A61P43/00 ,  A61K33/00

CPC classification number: A61K9/0024 ,  A01N59/16 ,  A61K9/0019 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/14 ,  A61K9/7007 ,  A61K33/24 ,  A61K33/38 ,  A61K33/40 ,  A61K47/34 ,  A61K47/38 ,  A61L15/46 ,  A61L17/145 ,  A61L27/30 ,  A61L29/10 ,  A61L31/082 ,  A61L2300/102 ,  A61L2300/104 ,  A61L2300/404 ,  A61L2300/452 ,  A61L2300/606 ,  A61L2300/624 ,  A61L2300/63 ,  Y10S424/15 ,  Y10S514/825 ,  Y10S514/826 ,  Y10S514/829 ,  Y10S514/83 ,  Y10S514/849 ,  Y10S514/851 ,  Y10S514/853 ,  Y10S514/861 ,  Y10S514/862 ,  Y10S514/864 ,  Y10S514/865 ,  Y10S514/88 ,  Y10S514/881 ,  Y10S514/882 ,  Y10S514/886 ,  Y10S514/887 ,  Y10S514/90 ,  Y10S514/901 ,  Y10S514/902 ,  Y10S514/912 ,  Y10S514/914 ,  Y10S514/925 ,  Y10S514/931 ,  Y10S514/932 ,  Y10S514/933 ,  Y10S514/934 ,  Y10S514/944 ,  Y10S514/951 ,  Y10S514/953 ,  Y10S514/954 ,  Y10S514/956 ,  Y10S514/958 ,  Y10S514/964 ,  Y10S514/965 ,  Y10S514/966 ,  Y10S514/967 ,  Y10S514/968 ,  Y10S514/969 ,  Y10T428/31855 ,  A61K2300/00 ,  A01N25/04 ,  A01N25/10 ,  A01N25/12

Abstract: The invention relates to a method to induce apoptosis and to inhibit matrix metalloproteinases in a disease condition in a human or animal by contacting hyperplastic tissue, tumor tissue, or a cancerous lesion with one or more antimicrobial metals, preferably formed with atomic disorder, and preferably in a nanocrystalline form. The nanocrystalline antimicrobial metal of choise may be used in the form of a nanocrystalline coating of one or more antimicrobial metals, a nanocrystalline powder of one or more antimicrobial metals , or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial metals .

Abstract translation: 本发明涉及通过使增生组织，肿瘤组织或癌性​​病变与一种或多种抗原性金属（优选以原子病形成的）接触来诱导细胞凋亡和在人或动物的疾病状态中抑制基质金属蛋白酶的方法， 呈纳米晶体形式。 选择的纳米晶体抗微生物金属可以以一种或多种抗微生物金属的纳米晶体涂层的形式使用，一种或多种抗微生物金属的纳米晶体粉末，或含有来自纳米晶体粉末或一种或多种抗微生物剂的纳米晶体粉末的溶解物质的溶液 金属。

公开(公告)号：WO02009729A2

公开(公告)日：2002-02-07

申请号：PCT/CA2001/001078

申请日：2001-07-27

IPC: A61K9/06 ,  A61K8/19 ,  A61K9/08 ,  A61K9/70 ,  A61K33/24 ,  A61K33/38 ,  A61K47/32 ,  A61K47/38 ,  A61P17/06 ,  A61P17/12 ,  A61Q17/00 ,  A61Q19/00 ,  A61K33/00

CPC classification number: A61Q17/005 ,  A61K8/19 ,  A61K9/0014 ,  A61K9/7023 ,  A61K33/38 ,  A61K47/32 ,  A61K47/38 ,  A61K2800/413 ,  A61Q19/00 ,  B82Y5/00 ,  Y10S514/86 ,  Y10S514/861 ,  Y10S514/863 ,  Y10S514/864 ,  Y10S514/886 ,  Y10S514/887 ,  Y10S514/944 ,  Y10S514/951 ,  Y10S514/963

Abstract: The invention relates to the use of one or more noble metals selected from silver, gold, platinum, and palladium but most preferably silver, in a nanocrystalline form, for the treatment of a hyperproliferative skin disorder or disease such as psoriasis. Among the noble metals, silver is preferred for such treatment. The nanocrystalline noble metal of choice may be used in the form of a nanocrystalline coating of one or more noble metals, a nanocrystalline powder of one or more noble metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more noble metals.

Abstract translation: 本发明涉及一种或多种选自银，金，铂和钯，但最优选银的贵金属以纳米晶形式用于治疗过度增生性皮肤病或疾病如牛皮癣的用途。 在贵金属中，优选这种处理的银。 所选择的纳米晶体贵金属可以以一种或多种贵金属的纳米晶体涂层，一种或多种贵金属的纳米晶体粉末或含有一种或多种贵金属的纳米晶体粉末或涂层的溶解物质的溶液的形式使用 金属。

公开(公告)号：WO01021150A1

公开(公告)日：2001-03-29

申请号：PCT/FR2000/002600

申请日：2000-09-20

IPC: A23K1/16 ,  A23L1/30 ,  A61K8/37 ,  A61K8/49 ,  A61K8/63 ,  A61K8/67 ,  A61K8/68 ,  A61K8/92 ,  A61K36/00 ,  A61K36/28 ,  A61K36/48 ,  A61K36/54 ,  A61P17/00 ,  A61P17/04 ,  A61P17/10 ,  A61Q19/00 ,  A61Q19/10 ,  A61K7/48 ,  A61K35/78

CPC classification number: A61Q19/10 ,  A23K20/158 ,  A23L33/11 ,  A23L33/115 ,  A61K8/375 ,  A61K8/4973 ,  A61K8/63 ,  A61K8/678 ,  A61K8/68 ,  A61K8/922 ,  A61K36/28 ,  A61K36/48 ,  A61K36/54 ,  A61K45/06 ,  A61K2800/75 ,  A61Q19/00 ,  A61Q19/004 ,  A61Q19/005 ,  A61Q19/007 ,  A61Q19/008 ,  Y10S514/859 ,  Y10S514/861 ,  Y10S514/863 ,  A61K2300/00

Abstract: The invention concerns the use of at least a vegetable oil product selected among the group consisting of vegetable oil oleic distillates, vegetable oil unsaponifiable matters, vegetable oil furan lipids and mixtures thereof, as agents for increasing skin lipid synthesis, in particular lipids of the epidermal skin barrier, in or for preparing a composition containing a pharmaceutically or dermatologically acceptable medium. The use enables to prevent and/or treat deterioration of the skin barrier (dry skin, skin subjected to actinic radiation, ichthyosis, acne, xerosis, atopic dermatitis, sensitive skin, chafing and reactive skin, itching and the like)

Abstract translation: 本发明涉及使用至少一种选自植物油油酸馏出物，植物油不皂化物质，植物油呋喃脂质及其混合物的植物油产品作为增加皮肤脂质合成的药剂，特别是表皮脂质 皮肤屏障，用于制备含有药学或皮肤病学可接受的培养基的组合物。 该用途能够防止和/或治疗皮肤屏障（干性皮肤，受光化辐射，鱼鳞病，痤疮，干性病，特应性皮炎，敏感性皮肤，擦伤和反应性皮肤，瘙痒等）的恶化。

公开(公告)号：WO9966918A9

公开(公告)日：2000-03-30

申请号：PCT/US9914237

申请日：1999-06-22

Applicant: MEDINOX INC ,  LAI CHING SAN ,  VASSILEV VASSIL

Inventor： LAI CHING-SAN ,  VASSILEV VASSIL

IPC: A61K45/00 ,  A61K31/145 ,  A61K31/27 ,  A61K31/4025 ,  A61K31/5377 ,  A61K45/06 ,  A61P1/00 ,  A61P1/04 ,  A61P3/10 ,  A61P7/00 ,  A61P9/00 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P43/00 ,  A61K31/105

CPC classification number: A61K31/145 ,  A61K31/4025 ,  A61K31/5377 ,  A61K45/06 ,  Y10S514/825 ,  Y10S514/838 ,  Y10S514/851 ,  Y10S514/861 ,  Y10S514/863 ,  Y10S514/866 ,  Y10S514/885 ,  Y10S514/903 ,  Y10S514/909 ,  Y10S514/912 ,  Y10S514/925

Abstract: The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

Abstract translation: 本发明提供了一种新颖的二硫代氨基甲酸酯二硫化物二聚体，其可用于各种治疗处理，单独或与其它活性剂组合。 在一种方法中，二硫代氨基甲酸二硫化物衍生物与灭活（或抑制产生）诱导一氧化氮合成酶表达的物质共同施用，以减少这种物质的产生，同时还原一氧化氮 主题级别。 在另一个实施方案中，通过给予二硫代氨基甲酸二硫化物衍生物来清除游离铁离子，例如在接受蒽环类化疗的受试者中游离铁离子水平降低。 在另一个实施方案中，通过施用二硫代氨基甲酸盐的二硫化物衍生物以使受试者中的氰化物结合，在受试者中氰化物水平降低。 在另一方面，本发明涉及可用于这种治疗方法的组合物和制剂。

公开(公告)号：WO9927924A3

公开(公告)日：1999-10-07

申请号：PCT/FR9802584

申请日：1998-12-01

Applicant: GALDERMA SA ,  BERGER ALVIN ,  JOMARD ANDRE

Inventor： BERGER ALVIN ,  JOMARD ANDRE

IPC: A61K8/30 ,  A61K8/00 ,  A61K8/36 ,  A61K8/96 ,  A61K8/98 ,  A61K31/20 ,  A61K31/202 ,  A61K31/232 ,  A61K35/60 ,  A61P11/00 ,  A61P29/00 ,  A61Q17/00

CPC classification number: A61K31/202 ,  Y10S514/844 ,  Y10S514/858 ,  Y10S514/859 ,  Y10S514/861 ,  Y10S514/863 ,  Y10S514/864 ,  Y10S514/887 ,  Y10S514/943

Abstract: The invention concerns fatty acid uninterrupted by a methylene as anti-inflammatory agents in superficial tissues of mammals, more particularly a pharmaceutical or cosmetic topical composition comprising, as active principle, at least one fatty acid non-interrupted by a methylene corresponding to formula (I), in which the fatty acid uninterrupted by a methylene is in the form of an acid, a salt or an ester, and R is a C1-C5 alkyl group and R is a C2-C6 alkyl group, preferably wherein the fatty acid uninterrupted by a methylene is the 20:3(5,11,14). Said fatty acids uninterrupted by a methylene are used for preparing a composition for modulating the metabolism of lipids in the superficial tissues of mammals.

Abstract translation: 本发明涉及在哺乳动物的表面组织中作为抗炎剂不被亚甲基中断的脂肪酸，更具体地涉及包含作为活性成分的至少一种不被对应于式（I）的亚甲基中断的脂肪酸的药物或美容用局部用组合物 ），其中未被亚甲基中断的脂肪酸为酸，盐或酯的形式，并且R 1为C 1 -C 5烷基并且R 2为C 2 -C 6烷基， 优选其中未被亚甲基中断的脂肪酸是20：3（5,11,14）。 所述不被亚甲基中断的脂肪酸用于制备用于调节哺乳动物表面组织中脂质代谢的组合物。

公开(公告)号：WO9924042A3

公开(公告)日：1999-07-22

申请号：PCT/US9823226

申请日：1998-11-05

Applicant: SCHERING CORP ,  ENDORECHERCHE INC

Inventor： SEQUEIRA JOEL A ,  LABRIE FERNAND ,  MAHASHABDE SHANSHANK ,  DEANGELIS NICHOLAS ,  MERAND YVES ,  FOURNIER MARC

IPC: A61K9/06 ,  A61K31/567 ,  A61K47/10 ,  A61K47/38 ,  A61P5/28 ,  A61P17/00 ,  A61P17/08 ,  A61P17/14 ,  A61P43/00 ,  A61K31/565

CPC classification number: A61K31/569 ,  A61K9/0014 ,  A61K31/575 ,  A61K47/10 ,  A61K47/38 ,  Y10S514/859 ,  Y10S514/861 ,  Y10S514/863 ,  Y10S514/864 ,  Y10S514/944

Abstract: Pharmaceutical compositions for the topical treatment of androgen-related conditions, e.g., acne in humans containing an amount of the compound represented by formula (II) effective for the topical treatment of the androgen-related conditions, e.g., acne dissolved in an alcohol-water solvent system, such as ethanol-water [97.6:2.4(w/w)] and having an apparent pH in the range of about 3.5 to 4.5, and containing a gelling agent are disclosed.

Abstract translation: 用于局部治疗雄激素相关病症的药物组合物，例如人中的痤疮，其含有对局部治疗雄激素相关病症有效的式（II）代表的化合物的量，例如溶于醇 - 水中的痤疮 溶剂体系如乙醇 - 水[97.6：2.4（w / w）]，并具有约3.5至4.5的表观pH，并含有胶凝剂。

公开(公告)号：WO99024042A2

公开(公告)日：1999-05-20

申请号：PCT/US1998/023226

申请日：1998-11-05

IPC: A61K9/06 ,  A61K31/567 ,  A61K47/10 ,  A61K47/38 ,  A61P5/28 ,  A61P17/00 ,  A61P17/08 ,  A61P17/14 ,  A61P43/00 ,  A61K31/565

CPC classification number: A61K31/569 ,  A61K9/0014 ,  A61K31/575 ,  A61K47/10 ,  A61K47/38 ,  Y10S514/859 ,  Y10S514/861 ,  Y10S514/863 ,  Y10S514/864 ,  Y10S514/944

Abstract: Pharmaceutical compositions for the topical treatment of androgen-related conditions, e.g., acne in humans containing an amount of the compound represented by formula (II) effective for the topical treatment of the androgen-related conditions, e.g., acne dissolved in an alcohol-water solvent system, such as ethanol-water [97.6:2.4(w/w)] and having an apparent pH in the range of about 3.5 to 4.5, and containing a gelling agent are disclosed.

Abstract translation: 用于局部治疗雄激素相关病症的药物组合物，例如，含有一定量的由式（II）表示的化合物用于局部治疗雄激素相关病症（例如溶解在酒精水中的痤疮）的人中的痤疮 溶剂系统，如乙醇 - 水[97.6:2.4（w / w）]，表观pH在约3.5至4.5范围内，并含有胶凝剂。

公开(公告)号：WO98040447A1

公开(公告)日：1998-09-17

申请号：PCT/FR1998/000488

申请日：1998-03-11

IPC: A61K8/96 ,  A61K8/97 ,  A61K35/04 ,  A61Q5/00 ,  A61Q19/00 ,  B60K15/05 ,  C10C1/16 ,  C10C3/06 ,  C10C1/04 ,  C10C1/08 ,  A61K7/48

CPC classification number: A61K35/04 ,  A61K8/97 ,  A61Q5/006 ,  A61Q19/00 ,  B60K15/05 ,  C10C1/16 ,  C10C3/06 ,  Y10S514/861 ,  Y10S514/863 ,  Y10S514/864 ,  Y10S514/88 ,  Y10S514/881

Abstract: The invention concerns a coal tar extract with reduced polycyclic aromatic hydrocarbon content and a method for obtaining same using two sequentially linked distillation systems. The invention also concerns cosmetic and dermatological preparations containing said resulting coal tar extract .

Abstract translation: 本发明涉及具有降低的多环芳烃含量的煤焦油提取物和使用两个顺序连接的蒸馏系统获得相同方法。 本发明还涉及含有所述所得煤焦油提取物的化妆品和皮肤病学制剂。